Delcath Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:05 pm EST
Share
Delcath Systems, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.434 million compared to USD 0.906 million a year ago. Net loss was USD 20.34 million compared to USD 8.88 million a year ago. Basic loss per share from continuing operations was USD 1.14 compared to USD 0.96 a year ago. Diluted loss per share from continuing operations was USD 1.14 compared to USD 0.96 a year ago.
For the nine months, revenue was USD 1.53 million compared to USD 2.08 million a year ago. Net loss was USD 36.54 million compared to USD 28.04 million a year ago. Basic loss per share from continuing operations was USD 2.61 compared to USD 3.29 a year ago. Diluted loss per share from continuing operations was USD 2.61 compared to USD 3.29 a year ago.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).